TY - JOUR
T1 - Basic science and translational implications of current knowledge on neuroendocrine tumors
AU - Fernandez-Cuesta, Lynnette
AU - Alcala, Nicolas
AU - Mathian, Emilie
AU - Derks, Jules
AU - Thirlwell, Chrissie
AU - Dayton, Talya
AU - Marinoni, Ilaria
AU - Perren, Aurel
AU - Walter, Thomas
AU - Foll, Matthieu
N1 - Funding Information:
We extend our gratitude to all rare cancers genomics initiative collaborators (https://rarecancersgenomics.com/) for their valuable contributions to the discussions, which greatly enriched the Review manuscript. Where authors are identified as personnel of the International Agency for Research on Cancer/WHO, the authors alone are responsible for the views expressed in this article and they do not necessarily represent the decisions, policy, or views of the International Agency for Research on Cancer/WHO.
Publisher Copyright:
© 2025, Fernandez-Cuesta et al.
PY - 2025/3/3
Y1 - 2025/3/3
N2 - Neuroendocrine tumors (NETs) are a diverse group of malignancies that can occur in various organs, with a notable prevalence in the lungs and gastrointestinal tract, which are the focus of this Review. Although NETs are rare in individual organs, their incidence has increased over recent decades, highlighting the urgent need for current classification systems to evolve by incorporating recent advances in the understanding of NET biology. Several omics studies have revealed molecular subtypes, which, when integrated into existing classification frameworks, may provide more clinically relevant insights for patients with NETs. This Review examines recent progress in elucidating the biology of NETs, with a particular emphasis on the tumor microenvironment and cells of origin. The existence of different cells of origin, which may contribute to distinct molecular groups, along with profiles of immune infiltration - despite being generally low - could explain the emergence of more aggressive cases and the potential for metastatic progression. Given the molecular heterogeneity of NETs and the diversity of their microenvironments and different cells of origin, there is an urgent need to develop morphomolecular classification systems. Such systems would make it possible to better characterize tumor progression, identify new therapeutic targets, and, ultimately, guide the development of personalized therapies.
AB - Neuroendocrine tumors (NETs) are a diverse group of malignancies that can occur in various organs, with a notable prevalence in the lungs and gastrointestinal tract, which are the focus of this Review. Although NETs are rare in individual organs, their incidence has increased over recent decades, highlighting the urgent need for current classification systems to evolve by incorporating recent advances in the understanding of NET biology. Several omics studies have revealed molecular subtypes, which, when integrated into existing classification frameworks, may provide more clinically relevant insights for patients with NETs. This Review examines recent progress in elucidating the biology of NETs, with a particular emphasis on the tumor microenvironment and cells of origin. The existence of different cells of origin, which may contribute to distinct molecular groups, along with profiles of immune infiltration - despite being generally low - could explain the emergence of more aggressive cases and the potential for metastatic progression. Given the molecular heterogeneity of NETs and the diversity of their microenvironments and different cells of origin, there is an urgent need to develop morphomolecular classification systems. Such systems would make it possible to better characterize tumor progression, identify new therapeutic targets, and, ultimately, guide the development of personalized therapies.
U2 - 10.1172/JCI186702
DO - 10.1172/JCI186702
M3 - (Systematic) Review article
SN - 0021-9738
VL - 135
JO - Journal of Clinical Investigation
JF - Journal of Clinical Investigation
IS - 5
M1 - e186702
ER -